Last updated: July 11, 2026

Executive summary: ALDACTAZIDE (spironolactone + hydrochlorothiazide) is a long-established, off-patent fixed-dose combination marketed for hypertension and edema. The drug’s financial trajectory is primarily driven by (1) ongoing erosion from authorized and unauthorized generics, (2) pricing pressure typical of older, widely substituted oral diuretics, and (3) supply and formulary access rather than brand exclusivity. Patent leverage is limited because the underlying actives and most fixed-dose combination claims are long past filing windows, making near-term volume and revenue growth unlikely; the base case is continued low-margin commoditization with periodic category-level demand stability.

What is ALDACTAZIDE and how does it make money in the market?

ALDACTAZIDE is a fixed-dose oral diuretic combination of spironolactone + hydrochlorothiazide. It is used in conditions where clinicians want both a potassium-sparing diuretic (spironolactone) and a thiazide diuretic (hydrochlorothiazide). The commercial model for ALDACTAZIDE is typical for older cardiovascular and diuretic products: brand pricing exists where brand retention remains on formularies, but generic substitution and therapeutic interchange tend to dominate overall demand.

Revenue drivers

Formulary placement in Medicare Part D and commercial plans for diuretic step therapy or preferred-agent lists.
Prescriber familiarity and inertia in chronic edema and hypertension regimens.
Availability and packaging (strengths, tablets, and manufacturer supply stability) influencing pharmacy fill rates.
Pricing relative to lower-cost generic equivalents of the same fixed-dose combination.

Demand characteristics

Chronic use in hypertension and edema leads to steadier baseline volumes than acute-care brands.
Competitive pressure is not tied to a single competitor but to broad substitution among:
- generic spironolactone + hydrochlorothiazide fixed dose,
- separate generic dosing of the two actives,
- alternative diuretic regimens and RAAS inhibitor strategies (where clinically appropriate).

Pricing and margin profile

As fixed-dose combinations age, net price typically compresses toward generic parity.
ALDACTAZIDE profitability is therefore more sensitive to gross-to-net management (rebates, discounts, chargebacks) and formulary access than to demand growth.

What market dynamics shape ALDACTAZIDE demand and pricing?

ALDACTAZIDE’s market dynamics are defined by four structural forces: generic availability, therapeutic interchange, payer cost controls, and guideline-driven prescribing patterns.

Generic substitution: why it matters most

The drug’s core competitive threat is generic fixed-dose competition and therapeutic interchange to separate generic components.
In practice, prescribers often accept equivalent dosing supplied by any approved generic manufacturer unless there is a specific intolerance, formulation requirement, or dosing schedule issue.

Payer policy and Medicare Part D behavior

Diuretics are frequently targeted in payer formularies as cost-minimizing therapy.
Plans typically steer patients to lowest-cost generics or preferred equivalents, limiting brand resilience.

Clinical switching drivers

Stability of electrolytes and renal function is the clinical focus, not brand.
Switching between equivalent spironolactone/hydrochlorothiazide products generally does not change therapeutic class, so substitution is common.

Supply chain and manufacturing risk

For oral tablets, supply is usually resilient, but intermittent shortages can create temporary market share swings across manufacturers.
These swings tend to be tactical, not structural, since supply normalizes.

When do key exclusivity windows end for ALDACTAZIDE?

Executive answer: ALDACTAZIDE is driven by active-ingredient and combination fixed-dose age, not by current brand exclusivity. For practical market planning, it is treated as effectively off-exclusivity with mature generic competition.

What exclusivity categories typically apply to older diuretic combinations

New chemical entity exclusivity does not apply to spironolactone or hydrochlorothiazide.
Any brand exclusivity from formulation changes would need to be tied to a specific new NDA supplement with a corresponding approval date and exclusivity grant. For an established fixed-dose combination product, this is generally not a near-term barrier for generics.

What patents protect ALDACTAZIDE and how strong is the patent estate?

Executive answer: Patent protection for ALDACTAZIDE is usually limited in commercial effect because the drug is a fixed-dose combination of widely known, older actives. In most market cases, exclusivity is not the constraint; generic approvals and substitution are.

Patent estate features that drive litigation and generic timing

Method-of-use patents, formulation patents, or specific dosing regimen claims can create secondary barriers, but those require clear linkage to an FDA-approved product and enforceable claim scope.
Absent an active, enforceable Orange Book barrier tied to the exact marketed strengths and approved labeling, the practical effect is that generics launch when regulatory and manufacturing readiness align.

How to read “market strong” versus “litigation strong”

Even if patents exist, generics can often launch via:
- Paragraph IV certifications to listed patents,
- “carve-out” label designs if allowed,
- design-around formulations or manufacturing changes not implicated by formulation claims.

For ALDACTAZIDE, the dominant market pattern is continued erosion rather than delayed entry.

What is the Orange Book status of ALDACTAZIDE?

Executive answer: ALDACTAZIDE is a mature product with an Orange Book profile dominated by long-expired or weakly binding protections in most cases, resulting in broad generic availability.

How Orange Book status maps to commercial risk

If only expired patents remain, the generic entry clock is effectively passed.
If unexpired patents remain, the key is whether they are tied to:
- the same dosage form (oral tablets),
- the same strengths,
- and the same labeling indications.
For a fixed-dose combination with entrenched competition, even “listed” patents often do not materially delay entry unless they are actively litigated.

Which companies compete in the ALDACTAZIDE market and how does share typically move?

ALDACTAZIDE competes in an over-the-counter-like competitive structure on a prescription basis: multiple approved generics with small differentiators.

Typical competitor set

Generic manufacturers and labelers of spironolactone/hydrochlorothiazide fixed-dose tablets (multiple DMFs and ANDA submissions across time).
Potential entrants at any time where FDA approval is granted and supply is established.

Share movement

Brand share typically tracks:
- generic price levels,
- pharmacy and PBM contracting,
- and whether a brand is preferred or incentivized.
Over time, brand share tends to decline and stabilize at a low baseline if any contractual or formulary factors sustain it.

What generic entry risks exist for ALDACTAZIDE?

Executive answer: Generic entry risk is structurally present but not a “timed event” because competition is already mature. The market risk now is incremental, tied to supply, pricing, and contracting rather than a single watershed entry.

Risk vectors

New entrants reduce net price and can trigger additional substitution even among current generics.
Price resets after PBM formulary updates.
Supply constraints can temporarily protect certain vendors, then dissipate.

What FDA regulatory status and review pathways matter for ALDACTAZIDE?

Executive answer: For this class, generics typically rely on abbreviated pathways with bioequivalence demonstrations and labeling that matches approved indications or is allowed through carve-outs.

Key regulatory mechanics affecting commercialization

ANDA bioequivalence and manufacturing controls.
Labeling compliance (including contraindications and warnings such as electrolyte monitoring, renal impairment cautions, and hyperkalemia risk).
FDA updates on safety labeling are generally shared across class members because the actives are the major risk drivers.

How does ALDACTAZIDE compare with alternative diuretic regimens and fixed-dose competitors?

Executive answer: ALDACTAZIDE’s comparative position is defined by the fixed combination’s convenience versus the broader option set of generic separate dosing and alternative diuretic classes.

Competitive comparisons that affect prescribing

Separate generics (spironolactone and hydrochlorothiazide individually) often win on price and allow dose flexibility.
Other fixed combinations may be preferred if they align with formulary tiers and patient management patterns.
Guideline-driven RAAS/diuretic sequencing influences how often diuretics are selected, but does not eliminate substitution pressure inside the diuretic class.

How might patent litigation and settlements affect ALDACTAZIDE’s financial trajectory?

Executive answer: Litigation can affect short-term share during generic launches. For ALDACTAZIDE, the main effect is typically incremental, because the drug is already established as widely generic.

What settlement structures usually do in mature fixed-dose markets

Reverse payment is unlikely to be a dominant driver unless a brand is still actively defended.
More common commercial impacts include:
- delayed launches by months to a year,
- agreed labeling limitations,
- and supply-based arrangements.

In a mature environment, litigation rarely reverses the long-term erosion trend.

What are the expected financial trajectory scenarios for ALDACTAZIDE?

Because the drug is mature, the scenario structure is about net revenue slope and margin compression more than about exclusivity cliffs.

Base case: steady volume, declining net price

Volumes remain supported by chronic use.
Net price continues trending toward generic parity.
Share among generics stabilizes; brand value erodes further unless contracting favors it.

Upside case: formulary retention plus supply stability

If the product retains preferred contracting in multiple PBMs and Medicare coverage, brand revenue can stabilize longer.
Supply stability across strengths can prevent fill-rate losses.

Downside case: additional generics plus stronger PBM tiering

More low-priced competitors or aggressive tiering drives additional substitution.
Net revenue declines faster than volume because of gross-to-net pressure.

Key metrics to track for ALDACTAZIDE commercialization and valuation

For business planning, the most decision-relevant metrics are those that predict price compression and formulary loss.

Metric	What to watch	Why it matters for ALDACTAZIDE
Net sales trend (brand and generic proxy)	12-month moving trend	Indicates whether volume supports or is overwhelmed by price erosion
TRx and scripts share	Monthly pharmacy claim trends	Shows competitive substitution and formulary impact
Wholesaler inventory	Shortage spikes or buildup	Explains temporary pricing/availability anomalies
PBM formulary and tier changes	Tiering moves and prior auth policies	Drives substitution velocity
Acquisition/contract changes	Rebates, MCO/PBM coverage	Direct effect on net price
Product discontinuations	Strength-level pullbacks	Can shift demand to competitors

Key Takeaways

ALDACTAZIDE is a mature fixed-dose oral diuretic combination with commercialization dominated by generic substitution and payer price pressure, not by brand exclusivity timing.
The financial trajectory is expected to follow a steady demand baseline with continuing net price compression, with any near-term swings driven by formulary/contracting and supply rather than by major regulatory barriers.
Patent and litigation dynamics are unlikely to be the primary lever in the short-to-medium term because the category is already widely genericized; commercial outcomes depend on net pricing mechanics and coverage.

FAQs

1) What drives ALDACTAZIDE market share changes month to month?
Formulary tier placement, PBM contracting, and supply availability of specific strengths typically drive the biggest short-term shifts.

2) Does ALDACTAZIDE face a “single expiration date” risk for generic entry?
No dominant timed exclusivity cliff is expected to govern the market because competition is already established and substitutions are ongoing.

3) How do separate generic spironolactone + hydrochlorothiazide dosing affect ALDACTAZIDE?
Separate dosing often wins on flexibility and can undercut fixed-dose price, increasing substitution pressure.

4) What regulatory events could materially change ALDACTAZIDE prescribing behavior?
Class-wide safety label updates or new contraindication/monitoring requirements can change practice, but these apply broadly across generics.

5) What is the most important commercial metric to monitor for ALDACTAZIDE investment decisions?
Net revenue trend tied to TRx and gross-to-net movement, because pricing compression is the main value driver in mature diuretic products.

References

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
FDA. Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	132
Patent Applications:	63
Drug Prices:	Drug price information for ALDACTAZIDE
What excipients (inactive ingredients) are in ALDACTAZIDE?	ALDACTAZIDE excipients list
DailyMed Link:	ALDACTAZIDE at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	ALDACTAZIDE	hydrochlorothiazide; spironolactone	TABLET;ORAL	012616-004	Dec 30, 1982	AB	RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Pfizer	ALDACTAZIDE	hydrochlorothiazide; spironolactone	TABLET;ORAL	012616-005	Dec 30, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

ALDACTAZIDE Drug Patent Profile

When do Aldactazide patents expire, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for ALDACTAZIDE

US Patents and Regulatory Information for ALDACTAZIDE

ALDACTAZIDE Market Dynamics and Financial Trajectory: Revenue Outlook, Generic/Biosimilar Risk, and Key Patent/Regulatory Drivers